Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Acorda Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ACOR
Nasdaq
8731
https://www.acorda.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Acorda Therapeutics Inc
Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024
- Mar 25th, 2024 8:01 pm
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
- Jan 11th, 2024 1:01 pm
Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Shares Bounce 53% But Its Business Still Trails The Industry
- Dec 18th, 2023 10:40 am
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q3 2023 Earnings Call Transcript
- Nov 14th, 2023 3:34 pm
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
- Nov 13th, 2023 9:01 pm
Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023
- Nov 6th, 2023 9:01 pm
Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®
- Nov 6th, 2023 1:00 pm
Acorda Therapeutics (ACOR): A Comprehensive Analysis of Its Market Value
- Aug 28th, 2023 4:42 pm
Acorda Therapeutics Reports Second Quarter 2023 Financial Results
- Aug 8th, 2023 8:01 pm
Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: "For The Fighters™"
- Aug 2nd, 2023 12:00 pm
Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023
- Aug 1st, 2023 12:00 pm
Tom Burns Elected to the Acorda Therapeutics Board of Directors
- Jun 28th, 2023 9:08 pm
Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Jun 26th, 2023 12:23 pm
Little Excitement Around Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Revenues
- Jun 5th, 2023 1:06 pm
Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split
- Jun 2nd, 2023 8:01 pm
Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split
- May 31st, 2023 8:01 pm
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
- May 30th, 2023 12:00 pm
Q1 2023 Acorda Therapeutics Inc Earnings Call
- May 12th, 2023 9:28 am
Acorda Therapeutics Reports First Quarter 2023 Financial Results
- May 11th, 2023 8:01 pm
3 Penny Stocks to Avoid as Interest Rates Rise in 2023
- May 11th, 2023 6:26 pm
Scroll